Tekmira will use Marina's technology to develop RNAi drugs

12/3/2012 | Genetic Engineering & Biotechnology News

Marina Biotech granted Tekmira Pharmaceuticals nonexclusive global rights to use its Unlocked Nucleobase Analog RNAi payload technology to develop RNAi drugs. The technology can help enhance the stability and reduce the undesired effects of RNAi drugs, the firms said. The deal entitles Marina to an upfront payment plus milestone fees and royalties on products arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI